RCMNY
BTAI icon

Rubric Capital Management (New York)’s BioXcel Therapeutics BTAI Stock Holding History

Rubric Capital Management (New York)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,478
Closed -$5.17M – 88
2022
Q2 		$5.17M Buy
24,478
+7,695
+46% +$1.62M 0.27% 59
2022
Q1 		$5.62M Buy
+16,783
New +$4.86M 0.2% 57

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rubric Capital Management (New York)'s BTAI Position: Q3 2022 in Review

Rubric Capital Management (New York) sold out of BioXcel Therapeutics (BTAI) in Q3 2022, closing a stake of 24,478 shares — an estimated $5.17M sold.

Rubric Capital Management (New York) first reported a position in BTAI in Q1 2022 and held it in 2 quarters. The position peaked at $5.62M in Q1 2022. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2022.

  • Rubric Capital Management (New York) reported no remaining BioXcel Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 24,478 BioXcel Therapeutics shares in Q3 2022, an estimated $5.17M.
  • Rubric Capital Management (New York) first reported a position in BioXcel Therapeutics in Q1 2022 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s BioXcel Therapeutics position peaked at $5.62M in Q1 2022.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.